Core Viewpoint - 华芢生物-B (02396) has experienced a significant decline in stock price, dropping over 12% to a new low of 18.6 HKD, which is a 51% decrease from its IPO price of 38.2 HKD [1] Company Overview - 华芢生物 is a biopharmaceutical company focused on the discovery, development, and commercialization of wound healing therapies [1] - As of December 5, 2025, the company has a pipeline of ten candidate products, with seven being PDGF candidate drugs, including two core products, Pro-101-1 and Pro-101-2 [1] Financial Performance - The company has not generated any revenue from product sales to date [1] - Projected net losses for the years 2023, 2024, and up to September 30, 2025, are 110 million, 210 million, and 130 million HKD respectively [1] - The majority of the net losses are attributed to research and development expenses as well as administrative costs [1]
华芢\生物-B早盘跌超12%创新低 较招股价已腰斩